Mixed US Market Action: Moderna Surges on Trial Results as Target Shares Slide

Key Facts

In a move reflecting sharp divergence across key sectors, US stocks showed mixed performance in premarket trading today. Moderna shares surged following the announcement of successful Phase 3 clinical trial results, significantly boosting investor confidence in the company's pipeline. Conversely, Target shares experienced a decline during early sessions, suggesting potential market concerns regarding the retailer's earnings outlook or guidance.

According to market data, the slide in Target (TGT) follows a closing price of $152.48 on August 18, 2026. This downward pressure contrasts with its previous session performance, where the stock reached a high of $154.26 and a low of $151.66. The divergent movement between Moderna's biotech-driven rally and Target's retail-sector weakness highlights the current selective nature of market sentiment.

Traders should watch for support levels near $151.66, the low reached at the close of August 18, 2026, to gauge the severity of the current slide. With no major upcoming economic catalysts listed in the immediate calendar, market participants will likely focus on the sustainability of Moderna's clinical-driven gains and further retail sector price action.